Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera
关键词
抽象
描述
Hydroxyurea is an established first-line treatment option currently approved in several European countries for Polycythemia Vera (PV) patients requiring a cytoreductive therapy (Barbui et al, 2011). Clinical trials have shown that HU is an effective drug for preventing thrombosis in PV compared to phlebotomy (Michiels et al, 1999).
The main concern of a long term treatment with HU is its potential leukaemogenicity: based on the mechanism of action, HU can potentially accelerate the accumulation of mutations in DNA and increase the risk of leukaemic transformation (Dingli et Tefferi, 2006). However, there is currently no clear clinical data to confirm leukaemogenicity of HU in patients with PV (Tefferi, 2012).
Even though IFN-alpha has shown its activity in PV in the 1980s, it is still considered as an experimental treatment in Europe due to pending approval in this indication (Barbui et al, 2011). It induces major or complete molecular remissions in patients with PV accompanied by a reduction in the risk of thrombosis and bleeding - the major determinants of morbidity in this indication (Hasselbalch, 2011). However, only low doses are tolerated and significant adverse effects from long-term use may limit its usefulness.
Pegylated interferons are better tolerated and are the preferred options of treatment in PV patients (Kiladjian et al, 2008) despite the lack of evidences based on well-designed randomized controlled clinical studies.
AOP2014 is a next generation pegylated interferon (Peg-P-IFN-alpha-2b), with the addition of proline in the N-terminal end.
AOP2014 like all interferon suppresses the malignant clone causing PV and subsequently is expected to possibly defer the onset of or avoid long term sequelae of PV. In addition, a reduction in the frequency of phlebotomies should be achieved. The peg-P-IFN-alpha-2b might potentially have a positive impact on reducing the drop-out rate compared to conventional IFNs. It is expected that the reduced frequency of administration of AOP2014 will contribute to higher compliance rates.
The maximum tolerated dose as well as the safety, efficacy and pharmacokinetics of AOP2014 were assessed in a phase I/II study in patients with PV. After 24 evaluable patients had entered the Phase I dose finding part, the MTD was defined at the level of 540 µg administered every two weeks. Another 27 patients were recruited in order to further investigate the drug efficacy and safety in PV. Efficacy results of AOP2014 were promising. By visit 18, 53.0% of the patients had reached complete response (12 evaluable patients). Adverse events were manageable and rarely necessitated treatment discontinuation.
AOP2014 was shown to have a prolonged plasma half-life with a concomitant increase in AUC. This is expected to enhance the therapeutic window of peg-IFN-alpha-2b.
The safety profile of type I interferons alpha is believed to be well characterized after clinical experience for nearly 20 years. Since the dose is carefully titrated to the optimal effective dose no additional risks for the patients are expected. HU, the IMP-comparator in the study, is the standard reference treatment in PV.
This phase III study was designed to compare, for the first time, the efficacy and safety of HU with a pegylated prolin-interferon alpha-2b (AOP2014) in patients with PV. Two populations will be assessed: HU naïve patients and patients currently treated or pre-treated with HU for less than 3 years, not responding to HU treatment (according to criteria in this protocol).
日期
| 最后验证: | 10/31/2016 |
| 首次提交: | 09/05/2013 |
| 提交的预估入学人数: | 09/19/2013 |
| 首次发布: | 09/24/2013 |
| 上次提交的更新: | 11/23/2016 |
| 最近更新发布: | 11/27/2016 |
| 实际学习开始日期: | 08/31/2013 |
| 预计主要完成日期: | 06/30/2016 |
| 预计完成日期: | 06/30/2016 |
状况或疾病
干预/治疗
Drug: Peg-P-IFN-alpha-2b (AOP2014)
Drug: Hydroxyurea
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Active Comparator: Hydroxyurea Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD | Drug: Hydroxyurea Hydroyurea capsules taken daily po |
| Experimental: Peg-P-IFN-alpha-2b (AOP2014) Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection | Drug: Peg-P-IFN-alpha-2b (AOP2014) Pegylated interferon alpha 2b given Q2W as SC injection |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: 1. 18 years or older 2. Diagnosis of Polycythemia Vera according to the WHO 2008 criteria (Barbui et al, 2011) with the mandatory presence of JAK2V617F mutation as the major disease criterion. 3. For previously cytoreduction untreated patients - documented need of cytoreductive treatment - leukocytosis (WBC>10G/L for two measurements within one week) 4. For patients currently treated or pre-treated with HU, all of the following criteria: - being non responders (as defined by the response criteria for primary endpoint) - total HU treatment duration shorter than three years - no documented resistance or intolerance as defined by modified Barosi et al, 2009 criteria 5. Hospital Anxiety and Depression Scale (HADS) score 0-7 on both subscales 6. Patients with HADS score of 8-10 inclusive on either or both of the subscales may be eligible following psychiatric assessment that excludes clinical significance of the observed symptoms in the context of potential treatment with an interferon alpha 7. Signed written informed consent Exclusion Criteria: 1. Any systematic cytoreduction for PV prior study entry with exception of HU for shorter than 3 years (see respective inclusion criterion) 2. Any contraindication to any of the IMPs (pegylated interferon or hydroxyurea) or their excipients 3. Any systemic exposure to a non-pegylated or pegylated interferon alpha 4. Documented autoimmune disease at screening or in the medical history 5. Clinically relevant pulmonary infiltrates, pneumonia, and pneumonitis at screening 6. Systemic infections, e.g. hepatitis B, hepatitis C, or HIV at screening 7. Known PV-related thromboembolic complications in the abdominal area (e.g. portal vein thrombosis, Budd-chiari syndrome) and/or splenectomy in the medical history 8. Any investigational drug less than 6 weeks prior to the first dose of study drug or not recovered from effects of prior administration of any investigational agent 9. History or presence of depression requiring treatment with antidepressant 10. HADS score equal to or above 11 on either or both of the subscales 11. Any risk of suicide at screening or previous suicide attempts 12. Any significant morbidity or abnormality which may interfere with the study participation 13. Pregnancy and breast-feeding females of reproductive potential and males not using effective means of contraception 14. History of active substance or alcohol abuse within the last year 15. Evidence of severe retinopathy (e.g. cytomegalovirus retinitis, macular degeneration) or clinically relevant ophthalmological disorder (due to diabetes mellitus or hypertension) 16. Thyroid dysfunction not adequately controlled 17. Patients tested positively with TgAb and / or TPOAb at screening 18. History of major organ transplantation 19. History of uncontrolled severe seizure disorder 20. Leukocytopenia at the time of screening 21. Thrombocytopenia at the time of screening 22. History of malignant disease, including solid tumours and hematological malignancies (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of the cervix that have been completely excised and are considered cured) within the last 3 years |
结果
主要结果指标
1. Disease response rate [Month 12]
次要成果指标
1. Disease response [at month 3, 6 and 9]
2. JAK2 allelic burden changes [at month 6 and 12]
3. time to response [from inclusion until first response confirmation]
4. duration of response [during the 12 months of study duration]
5. number of phlebotomies [from inclusion until month 12]
6. blood parameters [from inclusion until month 12]
7. spleen size [at month 3, 6, 9 and 12]
8. disease related symptoms [from inclusion until month 12]
9. adverse events [from inclusion until month 12]
10. protocol-specific adverse events of special interest [from inclusion until month 12]
